Cargando…

Public health impact and cost-effectiveness of catch-up 9-valent HPV vaccination of individuals through age 45 years in the United States

The Advisory Committee on Immunization Practices (ACIP) recommended catch-up 9-valent Human Papillomavirus (HPV) vaccination through age 26 years, and shared clinical decision-making for adults aged 27–45 years, compared with catch-up through age 26 years and 21 years for females and males, respecti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Daniels, Vincent, Prabhu, Vimalanand S., Palmer, Cody, Samant, Salome, Kothari, Smita, Roberts, Craig, Elbasha, Elamin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189092/ https://www.ncbi.nlm.nih.gov/pubmed/33427033 http://dx.doi.org/10.1080/21645515.2020.1852870

Ejemplares similares

Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study
por: Cody, Palmer, et al.
Publicado: (2021)

Median Age at HPV Infection Among Women in the United States: A Model-Based Analysis Informed by Real-world Data
por: Prabhu, Vimalanand S, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Routine Use of 15-Valent Pneumococcal Conjugate Vaccine in the US Pediatric Population
por: Huang, Min, et al.
Publicado: (2023)

Assessing the Health and Economic Outcomes of a 9-Valent HPV Vaccination Program in the United Kingdom
por: Owusu-Edusei, Kwame, et al.
Publicado: (2022)

HPV vaccination uptake and administration from 2006 to 2016 in a commercially insured population of the United States
por: Prabhu, Vimalanand S., et al.
Publicado: (2021)

The impact and cost-effectiveness of 9-valent human papillomavirus vaccine in adolescent females in Hong Kong
por: Cheung, Tak Hong, et al.
Publicado: (2021)

Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model
por: Insinga, Ralph P, et al.
Publicado: (2009)

Cost‑Effectiveness Risk‑Aversion Curves: Comparison of Risk-Adjusted Performance Measures and Expected-Utility Approaches
por: Elbasha, Elamin H.
Publicado: (2022)

Assessing the epidemiological impact on cervical cancer of switching from 4-valent to 9-valent HPV vaccine within a gender-neutral vaccination programme in Switzerland
por: Kind, André B., et al.
Publicado: (2020)

Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy
por: Mennini, Francesco Saverio, et al.
Publicado: (2017)

1737. Cost-Effectiveness Analysis of Catch-Up Vaccination with the 20-Valent Pneumococcal Conjugate Vaccine
por: Rozenbaum, Mark, et al.
Publicado: (2023)

Spotlight on the 9-valent HPV vaccine
por: Lopalco, Pier Luigi
Publicado: (2016)

Costs and Cost-Effectiveness of 9-Valent Human Papillomavirus (HPV) Vaccination in Two East African Countries
por: Kiatpongsan, Sorapop, et al.
Publicado: (2014)

Progression and regression of incident cervical HPV 6, 11, 16 and 18 infections in young women
por: Insinga, Ralph P, et al.
Publicado: (2007)

Public health impact and cost effectiveness of routine childhood vaccination for hepatitis a in Jordan: a dynamic model approach
por: Hayajneh, Wail A., et al.
Publicado: (2018)

Correction to: Public health impact and cost effectiveness of routine childhood vaccination for hepatitis a in Jordan: a dynamic model approach
por: Hayajneh, Wail A., et al.
Publicado: (2019)

Cutaneous HPV and alpha-mucosal 9-valent HPV sero-status associations
por: Rahman, Shams, et al.
Publicado: (2017)

Attributable Healthcare Resource Utilization and Costs for Patients With Primary and Recurrent Clostridium difficile Infection in the United States
por: Zhang, Dongmu, et al.
Publicado: (2018)

Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria
por: Boiron, L., et al.
Publicado: (2016)

Cost-effectiveness evaluations of the 9-Valent human papillomavirus (HPV) vaccine: Evidence from a systematic review
por: Mahumud, Rashidul Alam, et al.
Publicado: (2020)

Health impact and cost-effectiveness of implementing gender-neutral vaccination with the 9-valent HPV vaccine in Hong Kong
por: Cheung, Tak Hong, et al.
Publicado: (2023)

Intentions for catch-up HPV vaccination in Japan: an internet survey
por: Nakagawa, Satoshi, et al.
Publicado: (2023)

Universal varicella vaccination in Denmark: Modeling public health impact, age-shift, and cost-effectiveness
por: Burgess, Colleen, et al.
Publicado: (2023)

Correction: Cost-effectiveness evaluations of the 9-Valent human papillomavirus (HPV) vaccine: Evidence from a systematic review
por: Mahumud, Rashidul Alam, et al.
Publicado: (2023)

Vaccination and herd immunity thresholds in heterogeneous populations
por: Elbasha, Elamin H., et al.
Publicado: (2021)

Public health impact of 2-, 4-, and 9-valent HPV vaccination in females on cervical and noncervical diseases in men and women under different coverage scenarios in China: A simulation study
por: Diakite, Ibrahim, et al.
Publicado: (2023)

Correction: Universal varicella vaccination in Denmark: Modeling public health impact, age-shift, and cost-effectiveness
por: Burgess, Colleen, et al.
Publicado: (2023)

Chronic Hepatitis C Virus (HCV) Disease Burden and Cost in the United States
por: Razavi, Homie, et al.
Publicado: (2013)

Is the catch‐up program of HPV vaccination for Japanese adult women effective or not?
por: Kurokawa, Tetsuji
Publicado: (2020)

Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States
por: Gee, Julianne, et al.
Publicado: (2016)

Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models
por: Jit, Mark, et al.
Publicado: (2011)

Use of 9-Valent Human Papillomavirus (HPV) Vaccine: Updated HPV Vaccination Recommendations of the Advisory Committee on Immunization Practices
por: Petrosky, Emiko, et al.
Publicado: (2015)

Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada
por: Earnshaw, Stephanie R, et al.
Publicado: (2012)

Disparities among Japanese municipalities in recommendations for routine and catch‐up HPV vaccinations
por: Watanabe, Yuko, et al.
Publicado: (2023)

Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data
por: Strutton, David R, et al.
Publicado: (2012)

NC CATCH: Advancing Public Health Analytics
por: Studnicki, James, et al.
Publicado: (2010)

Clinical guideline for 9-valent HPV vaccine: Korean Society of Gynecologic Oncology Guideline
por: Min, Kyung-Jin, et al.
Publicado: (2019)

The Impact of 9-Valent HPV Vaccination on Couple Infertility Prevention: A Comprehensive Review
por: Ciavattini, Andrea, et al.
Publicado: (2021)

HPV and Cytology Testing in Women Undergoing 9-Valent HPV Opportunistic Vaccination: A Single-Cohort Follow Up Study
por: De Vincenzo, Rosa, et al.
Publicado: (2021)

Assessment of Health Benefits and Cost-Effectiveness of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccination in Kenyan Children
por: Ayieko, Philip, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_pqb7t040ate5ssndnq0g4cnof6